Skip to content
    FDA & Regulatory

    Inflation Reduction Act linked to drop in small molecule oncology studies

    Bowen et alTherapeutic innovation & regulatory science

    Inflation Reduction Act linked to drop in small molecule oncology studies
    An economic modeling study assessed the post-approval and late-stage research and development (R&D) impacts of the Inflation Reduction Act (IRA), analyzing 1,148 secondary trials from 364 FDA-approved medicines published from 2018 to 2025 obtained from Biomedtracker and ClinicalTrials.gov. Researchers used fractional logit regression to model the number of studies and fractional multinomial logit regression to model the share distribution of secondary indication studies across 19 disease groups to identify post-IRA shifts.
    Following the introduction of the IRA, small molecule follow-on studies in oncology exhibited a statistically significant 37% decline (p < 0.05), lead indication small molecule oncology approvals exhibited a statistically significant 27% decline (p < 0.05), and the share of orphan oncology studies exhibited a statistically significant 14% decline (p < 0.05). The authors noted that prior Congressional Budget Office analyses assumed limited impact on late-stage development and excluded post-approval innovation, concluding that the introduction of the IRA is associated with a decline in small molecule oncology studies and appears to negatively impact patients seeking new medicines, particularly those addressing metastatic late-stage cancers with a small molecule modality.

    Key Takeaways

    • Following the introduction of the IRA, small molecule follow-on studies in oncology exhibited a statistically significant 37% decline (p < 0.05).
    • Lead indication small molecule oncology approvals exhibited a statistically significant 27% decline post-IRA (p < 0.05).
    • The share of orphan oncology studies exhibited a statistically significant 14% decline after the IRA's introduction (p < 0.05).
    Read the original sourceTherapeutic innovation & regulatory science